Denali Therapeutics (NASDAQ:DNLI) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings data on Wednesday. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03), Briefing.com reports. During the same period in the previous year, the firm posted ($0.72) earnings per share.

Denali Therapeutics Stock Performance

NASDAQ DNLI traded up $0.12 during trading on Thursday, hitting $29.67. The stock had a trading volume of 645,270 shares, compared to its average volume of 1,071,237. The stock has a market capitalization of $4.25 billion, a price-to-earnings ratio of -10.37 and a beta of 1.40. Denali Therapeutics has a one year low of $14.56 and a one year high of $32.13. The stock has a 50 day simple moving average of $27.57 and a 200 day simple moving average of $23.36.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Bank of America upped their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Jefferies Financial Group increased their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Wedbush cut their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.90.

Insiders Place Their Bets

In related news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares of the company’s stock, valued at $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the transaction, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now directly owns 29,096 shares of the company’s stock, valued at $844,656.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.